Zacks Research Analysts Raise Earnings Estimates for ResMed

ResMed Inc. (NYSE:RMD - Free Report) - Equities researchers at Zacks Research raised their Q3 2025 earnings per share (EPS) estimates for ResMed in a report released on Wednesday, February 19th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings of $2.33 per share for the quarter, up from their prior forecast of $2.30. The consensus estimate for ResMed's current full-year earnings is $9.47 per share. Zacks Research also issued estimates for ResMed's Q4 2025 earnings at $2.39 EPS, FY2025 earnings at $9.35 EPS, Q1 2026 earnings at $2.28 EPS, Q2 2026 earnings at $2.37 EPS, Q3 2026 earnings at $2.50 EPS, FY2026 earnings at $9.63 EPS, Q1 2027 earnings at $2.49 EPS, Q2 2027 earnings at $2.60 EPS and FY2027 earnings at $10.61 EPS.

ResMed (NYSE:RMD - Get Free Report) last announced its earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%.

Several other equities analysts have also recently weighed in on the company. Stifel Nicolaus began coverage on ResMed in a report on Friday, December 13th. They issued a "hold" rating and a $250.00 price objective for the company. Needham & Company LLC reaffirmed a "hold" rating on shares of ResMed in a research note on Friday, January 31st. Piper Sandler increased their price objective on shares of ResMed from $252.00 to $260.00 and gave the stock a "neutral" rating in a research note on Friday, January 31st. The Goldman Sachs Group began coverage on shares of ResMed in a report on Thursday, January 16th. They issued a "buy" rating on the stock. Finally, JPMorgan Chase & Co. upped their price target on shares of ResMed from $270.00 to $286.00 and gave the stock an "overweight" rating in a report on Friday, January 31st. One research analyst has rated the stock with a sell rating, six have given a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $244.73.

ResMed Stock Performance

Shares of RMD traded up $6.08 during mid-day trading on Friday, hitting $235.73. 979,473 shares of the company's stock were exchanged, compared to its average volume of 982,692. The company has a quick ratio of 2.29, a current ratio of 3.33 and a debt-to-equity ratio of 0.13. ResMed has a 52 week low of $170.56 and a 52 week high of $263.05. The stock's 50-day simple moving average is $237.20 and its 200-day simple moving average is $239.52. The firm has a market cap of $34.62 billion, a price-to-earnings ratio of 27.83, a price-to-earnings-growth ratio of 1.53 and a beta of 0.70.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in RMD. Creative Planning increased its position in shares of ResMed by 15.4% during the third quarter. Creative Planning now owns 28,021 shares of the medical equipment provider's stock worth $6,840,000 after buying an additional 3,739 shares during the period. Blue Trust Inc. grew its holdings in ResMed by 359.4% during the 3rd quarter. Blue Trust Inc. now owns 974 shares of the medical equipment provider's stock worth $238,000 after acquiring an additional 762 shares during the period. Signaturefd LLC grew its holdings in ResMed by 1.7% during the 3rd quarter. Signaturefd LLC now owns 4,211 shares of the medical equipment provider's stock worth $1,028,000 after acquiring an additional 72 shares during the period. Lecap Asset Management Ltd. bought a new position in shares of ResMed in the 3rd quarter worth about $366,000. Finally, Commerzbank Aktiengesellschaft FI acquired a new position in shares of ResMed in the 3rd quarter valued at about $226,000. Institutional investors own 54.98% of the company's stock.

Insider Transactions at ResMed

In other news, CEO Michael J. Farrell sold 8,009 shares of the firm's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $236.77, for a total transaction of $1,896,290.93. Following the completion of the transaction, the chief executive officer now directly owns 455,472 shares in the company, valued at $107,842,105.44. This trade represents a 1.73 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $245.65, for a total value of $491,300.00. Following the completion of the transaction, the director now directly owns 81,218 shares in the company, valued at approximately $19,951,201.70. This represents a 2.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 12,147 shares of company stock worth $2,905,745. Company insiders own 0.71% of the company's stock.

ResMed Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th will be issued a dividend of $0.53 per share. The ex-dividend date is Thursday, February 13th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.90%. ResMed's dividend payout ratio (DPR) is presently 25.03%.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.